ECFC derived from PAH patients with pathogenic BMPR2-variants are more susceptible to LPS-induced permeability versus control ECFC and the effect is blocked by co-treatment with BMP9 (20). This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.